Engineering the Next Generation of T-Cell Engagers Through Selective Activation to Improve Specificity, Potency & Safety
Time: 10:00 am
day: Day Two
Details:
- Advancing beyond first-generation TCEs by unpacking the rationale behind engineering trispecific molecules to selectively engage CD8+ T-cells and how this improves specificity and reduces off-target activity in autoimmune disease
- Designing conditional activation for enhanced safety: Explore how activity restricted to target-bound TCEs helps minimize unwanted immune activation and cytokine release, with implications for autoimmune disease therapy
- Comparative engineering strategy: Contrasting AstraZeneca’s novel TCE architecture against first-generation engagers and competitor approaches, highlighting how molecular design choices influence preclinical performance and translational potential
